Centene (NYSE:CNC – Get Free Report) and InnovAge (NASDAQ:INNV – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, analyst recommendations, risk and institutional ownership.
Profitability
This table compares Centene and InnovAge’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Centene | 0.72% | 12.15% | 3.28% |
| InnovAge | 0.88% | 3.63% | 1.64% |
Risk & Volatility
Centene has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500. Comparatively, InnovAge has a beta of 0.16, meaning that its share price is 84% less volatile than the S&P 500.
Valuation and Earnings
This table compares Centene and InnovAge”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Centene | $194.78 billion | 0.16 | -$6.67 billion | $2.92 | 21.85 |
| InnovAge | $989.71 million | 1.27 | -$2.54 million | $0.06 | 153.00 |
InnovAge has lower revenue, but higher earnings than Centene. Centene is trading at a lower price-to-earnings ratio than InnovAge, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent ratings and price targets for Centene and InnovAge, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Centene | 1 | 11 | 9 | 0 | 2.38 |
| InnovAge | 1 | 1 | 1 | 1 | 2.50 |
Centene currently has a consensus price target of $75.20, indicating a potential upside of 17.86%. InnovAge has a consensus price target of $10.50, indicating a potential upside of 14.38%. Given Centene’s higher possible upside, equities research analysts clearly believe Centene is more favorable than InnovAge.
Insider and Institutional Ownership
93.6% of Centene shares are held by institutional investors. Comparatively, 12.3% of InnovAge shares are held by institutional investors. 0.4% of Centene shares are held by company insiders. Comparatively, 1.1% of InnovAge shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Centene beats InnovAge on 8 of the 15 factors compared between the two stocks.
About Centene
Centene Corporation is a U.S. health care company that provides managed care and related services, primarily for people enrolled in government-sponsored health programs. Its offerings include Medicaid and Medicare plans, as well as health insurance sold through the Affordable Care Act marketplace. Centene serves members through health plans and a network of health care providers. Its businesses include Ambetter, which offers marketplace health plans, and Wellcare, which provides Medicare-related coverage.
About InnovAge
InnovAge, Inc. provides integrated healthcare and social services to older adults through the Program of All-Inclusive Care for the Elderly (PACE). The program serves people who qualify for nursing-home-level care but can continue living in their communities with coordinated support. InnovAge’s services include primary and specialty care coordination, nursing, rehabilitation, social services, prescription medications, transportation, in-home assistance and adult day health services. Care is coordinated by interdisciplinary teams and delivered through a combination of community-based centers and support at home.
Receive News & Ratings for Centene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centene and related companies with MarketBeat.com's FREE daily email newsletter.
